Life Science Leader Chief Editor Blog Header image Life Science Leader Chief Editor Blog Header image

What Will Be The End Result Of Bullying Biopharma?
What Will Be The End Result Of Bullying Biopharma? If as adults we could invisibly walk on school playgrounds during recess, we might hear the stock response recited when encountering a bully — ‘Sticks and stones may break my bones, but words will never hurt me.”  Continue Reading...
BIO CEO 2016 Educational Sessions Provide Enlightenment
BIO CEO 2016 Educational Sessions Provide Enlightenment During this year’s BIO CEO Conference (partially covered here), much of my time was spent in the educational sessions, which I would rank as some of the best I have seen at any conference — ever. For example ...  Continue Reading...
Is Attending BIO CEO A Waste Of Your Time?
Is Attending BIO CEO A Waste Of Your Time? Sometimes it is worthwhile to stop and consider the value of your time, not from a financial perspective, but rather how much you’ve used and how much you have left. If you did, you might be much more discriminating in where you would choose to spend it. Consider this: the average U.S. male’s life expectancy is 76. This means that in less than 14,600 hours my time fuel tank will be exactly one-third full, or depending on your...  Continue Reading...
What Does It Take To Be The World’s Top Performing CEO?
What Does It Take To Be The World’s Top Performing CEO? In November 2015, the Harvard Business Review (HBR) announced the top 100 CEOs in the world. Though the list included household names like Starbucks (12), Nike (21), and Amazon (87), what is even more interesting than the fact that Novo Nordisk’s Lars Rebien Sørensen was ranked number one, was the healthcare industry as a whole had 13 CEOs in the top 100 — tying it for first with financial service (see Table 1). But if you dig ...  Continue Reading...
What Is The Solution To “High-Price” Drug Sticker Shock?
What Is The Solution To “High-Price” Drug Sticker Shock? Last November, lawmakers and the Obama administration began ratcheting up efforts targeted at pharmaceutical company’s “high-priced drugs.” Some view this as a sign that legislators are trying to bridge the political divide to tackle a key driver of rising healthcare costs. But are high-priced drugs and biopharmaceutical companies the most important driver to target?  Continue Reading...
What Surprised Me — And Didn’t — At J.P. Morgan 2016
What Surprised Me — And Didn’t — At J.P. Morgan 2016 Unfortunately, a minor mechanical issue involving one of my flights caused me to arrive a day late for the 34th Annual J.P. Morgan Healthcare Conference (JPM) in San Francisco (January 11-14). While missing Monday at one of biopharma’s biggest annual events (Twitter hashtag #JPM16) translates to a huge lost opportunity (i.e., not being able to attend 16 of 108 scheduled presentations/breakout sessions), when it comes to JPM, one day does...  Continue Reading...
What Is Going To Be The Next Big Thing For Biopharma In 2016?
What Is Going To Be The Next Big Thing For Biopharma In 2016? There are plenty of industry insights available, such as Life Science Leader’s comprehensive December 2015 Outlook issue for 2016 or our four-part trendsetter series. And while these provide a wealth of insight, I felt compelled to put together one last blog to prevent you from being blindsided by the “Next Big Thing” in biopharma in 2016.  Continue Reading...
What Guides Your Company?
What Guides Your Company? If you have ever seen an employee of Johnson and Johnson speak, you probably recall that at some point during their presentation they probably made reference to “Our Credo” — a J&J document that describes the values used to guide employee decision making. “Put simply, Our Credo challenges us to put the needs and well-being of the people we serve first.” Written in 1943 by Robert Wood Johnson, former chairman and ...  Continue Reading...
The Folly Of Burying Great Insight
The Folly Of Burying Great Insight Last week I posted “Why The Wall Street Journal’s U.S. Drug Price Comparison Misses The Mark,” a criticism of health and science deputy bureau chief Jeanne Whalen’s Dec. 1, 2015 article titled, “U.S. Drug Prices Dwarf Other Nations.” What bothered me about this article was that I felt it skewed the facts, sensationalized the issue, and seemed intent on stirring up controversy.  Continue Reading...
FDA/CMS Summit Demonstrates Need For Innovative Hiring Solutions
FDA/CMS Summit Demonstrates Need For Innovative Hiring Solutions When Janet Woodcock, M.D., kicked of this year’s FDA/CMS Summit for biopharmaceutical executives, the FDA’s director for the Center for Drug Evaluation & Research (CDER) did so by recapping what was achieved in 2015, as well as sharing her lengthy list of priorities for the coming year. According to Woodcock, the challenge to successful implementation of various priorities is analogous to keeping an airplane flying while at the...  Continue Reading...